NCT04282876 is a clinical trial of Degarelix in Bladder Cancer, sponsored by Aarhus University Hospital.

Who is sponsoring NCT04282876?

NCT04282876 is sponsored by Aarhus University Hospital.

What drugs are being tested in NCT04282876?

Interventions in NCT04282876: Degarelix.

What condition does NCT04282876 study?

NCT04282876 studies Bladder Cancer, Radiation Therapy Complication, Quality of Life.

Is NCT04282876 still recruiting?

NCT04282876 is currently status unknown. Last updated 8 August 2022.

Last reviewed 2022-08-08 · How we verify

NCT04282876

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Influence of Hormone Treatment in Radiation Therapy for Bladder Cancer

Status unknown Last updated 8 August 2022

What this trial tests

trial testing Degarelix in Bladder Cancer in 60 participants. Status unknown.

Timeline

19 February 2020

Primary endpoint
1 February 2024

31 October 2025

Quick facts

Lead sponsor	Aarhus University Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	60
Start date	19 February 2020
Primary completion	1 February 2024
Estimated completion	31 October 2025
Sites	1 location across Denmark

Drugs / interventions tested

Degarelix (degarelix) — full drug profile →

Conditions studied

Bladder Cancer — all drugs for Bladder Cancer →
Radiation Therapy Complication — all drugs for Radiation Therapy Complication →
Quality of Life — all drugs for Quality of Life →

Sponsor

Aarhus University Hospital

Who can join

18 and older, male only, with Bladder Cancer or Radiation Therapy Complication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bladder cancer is often treated with cystectomy or radiation therapy. Following radiation therapy patients will often have severe side effects from the treatment. Studies have suggested that simultanously treatment with androgen deprivation therapy during radiation therapy may be able to proctect stemcells in the bladder, thus improving tissue recovering post-radiation, which would result in improved bladder compliance following the treatment and ultimately result in fewer side effects and overall improved patient quality of life.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Sex Hormone Receptor Signaling in Bladder Cancer: A Potential Target for Enhancing the Efficacy of Conventional Non-Surgical Therapy.
Ide H, Miyamoto H. · · 2021 · cited 25× · PMID 34064926 · DOI 10.3390/cells10051169
Roles of Androgen Receptor Signaling in Urothelial Carcinoma.
Sundi D, Collier KA, Yang Y, Diaz DA, et al · · 2024 · cited 9× · PMID 38398136 · DOI 10.3390/cancers16040746
Assessment of lower urinary tract symptoms and their impact on quality of life following radiation therapy for bladder cancer.
Hyldgaard J, Als AB, Ulhøi B, Jensen J, et al · · 2025 · PMID 40747125 · DOI 10.14440/bladder.2024.0046

Verify or expand the search:

Other trials of Degarelix

Trials testing the same drug.

NCT07335796 — A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer · Phase 2 · recruiting
NCT05873192 — Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer · Phase 2 · recruiting
NCT06378866 — Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivati · Phase 2 · recruiting
NCT06264882 — Cardiometabolic Consequences of the Loss of Ovarian Function · Phase 4 · recruiting
NCT05501704 — ETHAN - ET for Male BC · Phase 2 · recruiting

Other recruiting trials for Bladder Cancer

Currently open trials in the same condition.

NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting

Other Aarhus University Hospital trials

Trials by the same sponsor.

NCT07432802 — Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer · NA · not yet recruiting
NCT07499336 — UNDERSTANDING THE T-CELL AND B-CELL RECEPTOR REPERTOIRE IN CHILDREN AND YOUNG ADULTS WITH ANTI-DRUG ANTIBODIES AGAINST P · not yet recruiting
NCT07454486 — TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cance · not yet recruiting
NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT07426250 — Clinical Utility of ctDNA in the Treatment of Oligometastatic Disease · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04282876 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aarhus University Hospital
Last refreshed: 8 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04282876.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing